Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25421947 | 1.00 | USP2 (0.48) | USP2SPHK1DNM1ALDH1A1CNR1 | |
| SCHEMBL3873682 | 1.00 | USP2 (0.48) | USP2SPHK1DNM1ALDH1A1CNR1 | |
| SCHEMBL11981865 | 0.92 | USP2 (0.38) | USP2SPHK1ALDH1A1CNR1CNR2 | |
| SCHEMBL11981862 | 0.92 | USP2 (0.38) | USP2SPHK1ALDH1A1CNR1CNR2 | |
| SCHEMBL11981859 | 0.92 | USP2 (0.38) | USP2SPHK1ALDH1A1CNR1CNR2 | |
| SCHEMBL11981857 | 0.92 | USP2 (0.38) | USP2SPHK1ALDH1A1CNR1CNR2 | |
| SCHEMBL28002018 | 0.83 | SPHK1 (0.42) | USP2SPHK1DNM1ALDH1A1CNR1 | |
| SCHEMBL1944097 | 0.82 | DNM1 (0.55) | USP2SPHK1DNM1ALDH1A1HTT | |
| SCHEMBL20788845 | 0.82 | USP2 (0.50) | USP2SPHK1DNM1ALDH1A1CNR1 | |
| SCHEMBL20788838 | 0.82 | USP2 (0.50) | USP2SPHK1DNM1ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10156566-B2 | Detoxification of microbial virulence factors in oral cavity | THE PROCTER & GAMBLE COMPANY (US) | 2018-12-18 | — | — | US | disclosed |
| EP-3292215-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | The Procter and Gamble Company (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170119643-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | THE PROCTER & GAMBLE COMPANY | 2017-05-04 | — | — | US | disclosed |
| WO-2016179561-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | THE PROCTER & GAMBLE COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-8394785-B2 | Methods for the treatment and amelioration of urticaria | JADO TECHNOLOGIES GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-20110263531-A1 | METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS | JADO TECHNOLOGIES GMBH | 2011-10-27 | — | — | US | disclosed |
| CN-1202863-C | Antigen delivery system comprising a monoglyceride or diglyceride derivative as an adjuvant | MEDICINE DEV CO LTD (IS) | 2005-05-25 | — | — | CN | disclosed |
| CN-1262626-A | Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant | MEDICINE DEV CO LTD (IS) | 2000-08-09 | — | — | CN | disclosed |
| EP-0284395-B1 | NOVEL GLYCEROL DERIVATIVE AND ANTI-HYPERTENSIVE AGENT | NIPPON CHEMIPHAR CO., LTD. (JP) | 1993-06-23 | — | — | EP | disclosed |
| US-5183811-A | Glycerol derivative and anti-hypertensive agent | NIPPON CHEMIPHAR CO., LTD. (JP) | 1993-02-02 | — | — | US | disclosed |
| US-4962096-A | WITH REDUCED PLATELET AGGREGATING ACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 1990-10-09 | — | — | US | disclosed |
| US-4827011-A | QUATERNARY AMMONIUM INNER SALTS | AMERICAN CYANAMID COMPANY (US) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119643-A1 | DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY | GSTM2, GSTA2, GSTA1 | USP2 493/4885SPHK1 3963/4885DNM1 1636/4885 |
| US-10156566-B2 | Detoxification of microbial virulence factors in oral cavity | GSTM2, GSTA2, GSTA1 | USP2 493/4885SPHK1 3963/4885DNM1 1636/4885 |
| US-20110263531-A1 | METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS | PHOSPHO1, SMPD3, SMPD1 | USP2 3107/4885SPHK1 35/4885DNM1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.